by barry101 | Sep 23, 2024 | Press Releases
Data recently presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer Treatment with Annamycin results in statistically significant inhibition of tumor growth and extension of survival in orthotopic lung...
by barry101 | Sep 16, 2024 | Press Releases
Wally Klemp, CEO of Moleculin, discusses the Company’s recent update on the Phase 2 clinical trial of STAT3 inhibitor in combination with radiation for the treatment of glioblastoma Watch the “What This Means” video here HOUSTON, Sept. 16, 2024...
by barry101 | Sep 9, 2024 | Press Releases
– Investigator-initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin – Funding for study provided by NIH and BrainUp® – Trial combines WP1066 and radiation, which demonstrated both significant...
by barry101 | Sep 3, 2024 | Press Releases
HOUSTON, Sept. 3, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today...
by barry101 | Aug 26, 2024 | Press Releases
Live webcast on Wednesday, August 28th at 3:40 PM ET HOUSTON, Aug. 26, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug...
by barry101 | Aug 19, 2024 | Press Releases
$5.5 million financing upfront with up to an additional $11.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HOUSTON, Aug. 19, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the...
